

IgG-1 Monoclonal Antibody Vyvgart (Efgartimod Alfa-fcab) J9332 Prior Authorization Request Medicare Part B Form

Instructions: * Indicates required information – Form may be returned if required information is not provided. Please fax this request to the appropriate fax number listed at the bottom of the page.

	Date Req	uested	 					
	Requesto	r	Clinic name:		Phone		/ Fax	
MEMBER INFORMATION								
*Name:			*	*ID#:		*DOB:		
PRESCRIBER INFORMATION								
*Nar	me:		DM	□MD □FNP □DO □NP □PA *Phone:				
*Address:				*Fax:				
DISPENSING PROVIDER / ADMINISTRATION INFORMATION								
*Name: Phone:								
*Address:				Fax:				
PROCEDURE / PRODUCT INFORMATION								
HC	PC Code	Name of Drug	☐ Self-administered	Dose (Wt:	kg Ht:)	Frequency	End Date if known
□Chart notes attached. Other important information:								
Diagnosis: ICD10: Description:								
☐ Provider attests the diagnosis provided is an FDA-Approved indication for this drug								
CLINICAL INFORMATION								
 □ New Start or Initial Request: (Clinical documentation required for all requests) □ Provider has reviewed the attached "Criteria for Approval" and attests the member meets ALL required PA criteria. If not, please provide clinical rationale for formulary exception: 								
 □ Continuation Requests: (Clinical documentation required for all requests) □ Provider has reviewed the attached "Criteria for Continuation" and attests the member meets ALL required PA Continuation criteria. □ Patient had an adequate response or significant improvement while on this medication. If not, please provide clinical rationale for continuing this medication: 								
ACKNOWLEDGEMENT								
Any prinsuration insurations and the second	person who kn ance company ance act, whic	by providing material his a crime and subje	ired): It for authorization of coverage Illy false information or concea Icts such person to criminal and ITEE PAYMENT. PAYMENT IS BAS	ils material informat d civil penalties.	ion for the purpos	th the inter se of mislea	iding, commits a fr	audulent



Prior Authorization Group - IgG-1 Monoconal Antibody PA

Drug Name(s):

VYVGART
EFGARTIGIMOD ALFA-FCAB

Criteria for approval of Non-Formulary/Preferred Drug:

- 1. Prescribed for an approved FDA diagnosis (as listed below):
- 2. Drug meets the following utilization management criteria:
 - a. Documented trial and failure to 2 immunosuppressants
 - i. Failure is defined as an inability to improve the condition after at least 1 year of treatment
 - ii. Immunosuppressants include azathioprine, cyclosporine, methotrexate, mycophenolate, tacrolimus
 - b. Baseline Myasthenia-Gravis Activities of Daily Living (MG-ADL) of at least 5
- 3. Member does not have any clinically relevant contraindications, or CMS/Plan exclusions, to the requested drug.
 - If the member meets all these criteria, they may be approved by the Plan for the requested drug.
 - Quantity limits and Tiering will be determined by the Plan.

Exclusion Criteria:

N/A

Prescriber Restrictions:

Must be prescribed by, or in consultation with, a neurologist

Coverage Duration:

Approval will be for 6 months

 Must have a documented response to therapy evidenced by at least a 2-point reduction in the MG-ADL total score from baseline for reauthorization

FDA Indications:

Myasthenia gravis, Anti-acetylcholine antibody positive

Off-Label Uses:

Vyvgart

N/A

Age Restrictions:

Safety and effectiveness have not been established in pediatric patients

Other Clinical Consideration:

N/A

Resouces:

https://www-micromedexsolutions-

com.liboff.ohsu.edu/micromedex2/librarian/CS/A5E163/ND PR/evidencexpert/ND P/evidencexpert/DUPLICATIONSHIELDSYNC/955
E51/ND PG/evidencexpert/ND B/evidencexpert/ND AppProduct/evidencexpert/ND T/evidencexpert/PFActionId/evidencexpert.G
oToDashboard?docId=933502&contentSetId=100&title=Efgartigimod+Alfa-fcab&servicesTitle=Efgartigimod+Alfa-fcab&brandName=Vyvgart&UserMdxSearchTerm=vyvgart&=null#